Centre cover image credit: Emily Wyatt, Mark Davis, California Institute of Technology NIH funding from: National Cancer Institute. This image shows blood vessels (red), cell nuclei (blue), and human metastatic breast cancer cells (green) in a mouse’s brain, after intravenous administration of experimental nanoparticles that can cross the blood-brain barrier.

The successful launch of mRNA vaccines during the Covid-19 pandemic has not only spurred mRNA-related research across interdisciplinary groups, but also further validated the use of lipid nanoparticles as delivery approaches. This issue’s cover story delves into how the interest around exploring nanotechnology for drug delivery solutions has recently grown.

Also, in this month’s issue, we explore what is on the horizon for eConsent, a popular feature in decentralised clinical trial (DCT) space.  

Don’t miss an exclusive interview looking at the progress made in the decade since the first chimeric antigen receptor (CAR)-T therapy was successfully tested in a patient.

Also, this month’s thematic take digs into the varied facets of Environmental, Social and Governance (ESG)-related issues in the pharmaceutical industry.

All this and the latest pharma industry news, comment, and analysis from GlobalData.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

Read the latest issue of Pharma Technology Focus for all this and insights, and analysis from the pharmaceutical industry.

You can also subscribe here to receive email notifications when a new issue is available.